Core Viewpoint - A class action lawsuit has been filed against Picard Medical, Inc. (NYSE: PMI) on behalf of investors who acquired its securities between September 2, 2025, and October 31, 2025, due to allegations of a fraudulent stock promotion scheme [1] Allegations - The lawsuit alleges that Picard Medical failed to disclose involvement in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [1] - It is claimed that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [1] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] Stock Price Impact - On October 24, 2025, Picard Medical's stock price plummeted by 70%, dropping to $3.99 per share, and has since continued to decline to approximately $2.00 per share [1] Shareholder Actions - Shareholders may be eligible to participate in the class action and those wishing to serve as lead plaintiff must file their papers with the court by April 3, 2026 [1] - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [1] Legal Representation - Robbins LLP, a firm specializing in shareholder rights litigation, is representing the class action on a contingency fee basis, meaning shareholders pay no fees or expenses unless a recovery is achieved [1]

Core Viewpoint - A class action lawsuit has been filed against PomDoctor, Ltd. for allegedly making materially false and misleading statements during the class period from October 9, 2025, to December 11, 2025, affecting investors who purchased American Depositary Receipts [1][2] Group 1: Allegations - The complaint alleges that PomDoctor was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6] - It is claimed that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price, rendering their statements about business operations and prospects materially false and misleading [6] Group 2: Legal Process - Investors have until April 6, 2026, to seek appointments as lead plaintiff in the class action lawsuit [1][2] - The law firm Wolf Haldenstein Adler Freeman & Herz LLP, with over 125 years of experience in securities litigation, is leading the case and encourages affected investors to come forward [4]

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant stock price inflation during the class period from October 10, 2025, to November 12, 2025 [8]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [8]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [8]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [8]. Stock Price Movement - Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news justifying such a spike [8]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [8]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the required information to lift the suspension [8].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ:MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant stock price inflation during the class period from October 10, 2025, to November 12, 2025 [6]. Group 1: Allegations and Legal Actions - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The stock price surged from an initial public offering price of $4.00 to an all-time high of $29.36 per share without any fundamental news justifying such a spike [6]. Group 2: Trading Suspension and Investor Rights - Trading of Charming's stock was halted by the SEC on November 12, 2025, due to the company's failure to provide required information to lift the suspension [6]. - Investors who purchased Charming shares during the class period and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. to discuss their legal rights and options [4][6]. Group 3: Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in securities litigation and has a nationwide practice [5].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant price inflation of its shares during a specific period [6]. Group 1: Allegations - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders and affiliates allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that inflated the stock price [6]. Group 2: Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [6]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [6]. Group 3: Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the required information to lift the suspension [6]. Group 4: Legal Process - Investors who purchased Charming shares between October 10, 2025, and November 12, 2025, have until February 17, 2026, to apply to be appointed as lead plaintiff in the lawsuit [6].

Core Viewpoint - Charming Medical Limited is facing a class action lawsuit due to allegations of stock price manipulation through a fraudulent promotion scheme, which led to a significant and unjustified increase in its stock price [3]. Group 1: Company Overview - Charming Medical Limited operates in the wellness sector, integrating Traditional Chinese Medicine (TCM) with modern technology to offer wellness and beauty services and products for both women and men [3]. - The company's stock is traded on NASDAQ under the symbol "MCTA" [3]. Group 2: Stock Price Manipulation Allegations - The complaint against Charming Medical alleges violations of the Securities Act due to the suspension of its stock in November 2025, following an artificial price surge [3]. - Prior to the suspension, Charming's share price rose dramatically from the IPO price of $4.00 to an all-time high of $29.36 per share, without any fundamental news to justify this increase [3]. - Investigations revealed that the stock price was inflated by a social-media-based promotion scheme involving impersonators posing as legitimate financial advisors, which created a buying frenzy among retail investors [3]. Group 3: Legal Actions and Investor Support - The Portnoy Law Firm is advising investors who purchased Charming Medical securities between October 21, 2025, and November 12, 2025, to file a lead plaintiff motion by February 17, 2026 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss options for pursuing claims to recover losses [2].